The Dubai Health Authority (DHA) has inaugurated a Hospitality Care Centre dedicated to the treatment of infectious diseases, including Covid-19.
The specialised facility is located in the Dubai Industrial Zone and has 170 rooms spread across of three floors.
The state-of-the art centre includes clinics, pharmacy, laboratory, radiology and follow-up services.
It is operational 24×7 and has already begun receiving Covid-19 cases. There are 88 rooms dedicated for treatment of Covid-19 patients.
The center is located in the Dubai Industrial Zone and it consists of three floors, which include 88 dedicated rooms for the treatment of COVID-19 patients, from normal to critical cases.
— Dubai Media Office (@DXBMediaOffice) October 27, 2020
Patients will be treated under the supervision of staff from Rashid Hospital, since the centre is directly affiliated with the hospital.
Humaid Al Qutami, director-general of the DHA said that the authority had worked towards increasing the capacity of its medical facilities, in anticipation of any developments.
He added that the objective is for the facility in the future to become an international centre specialised in treating communicable diseases, providing highly advanced laboratory for radiology and diagnostic tests, and serving as unit for epidemiological research and studies.
Earlier this month, the authority launched three new dedicated Covid-19 testing facilities in the emirate at Al Rashidiya Majlis, Al Hamriya Port Majlis and Jumeirah 1 Port Majlis, in collaboration with the Community Development Authority Dubai.
Read: DHA opens three new Covid-19 testing facilities in Dubai
It takes the number of DHA centres exclusively for Covid-19 testing up to five – which includes those already opened at Al Shabab Al-Ahli and Al Nasr Clubs.
On Tuesday, the UAE reported 1,390 new cases, 1,708 recoveries and two deaths in the last 24 hours. The registered infection count has therefore risen to 127,624.
Read: Covid-19 update: UAE reports 1,390 cases; 466 infections registered in Oman
Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases
— GFB-887, a first-in-class highly potent and selective inhibitor of the TRPC5-Rac1 pathway, was well-tolerated in single ascending doses —
— GFB-887 induced dose-dependent reductions in urinary Rac1, demonstrating target engagement —
— TRPC5-Rac1 pathway overactivation is key cause of disease in substantial portion of patients with focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN) —
— Phase 2 clinical study of GFB-887 (TRACTION-2) underway; initial data expected in the first quarter of 2021 —
Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced for the first time results from its Phase 1 clinical trial evaluating GFB-887, a first-in-class highly potent and selective inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), in healthy volunteers. The data are being presented today at the virtual American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting.
Goldfinch Bio is developing GFB-887 as a precision medicine for patients with kidney diseases characterized by overactivation of the TRPC5-Rac1 pathway, including focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Overactivation of the TRPC5-Rac1 pathway leads to injury of podocytes, which are cells lining the kidney that, in their healthy state, prevent essential protein loss (proteinuria). Injury to podocytes causes podocyte loss, proteinuria and, eventually, kidney failure. TRPC5-Rac1 pathway overactivation is the key cause of disease in a substantial portion of FSGS and DN patients, and there are currently no approved drugs that specifically target the TRPC5-Rac1 pathway in these diseases.
“We are excited to share these first-in-human data, which demonstrate that GFB-887 is well-tolerated and suggest a dose-dependent reduction in urinary Rac1, confirming GFB-887 target engagement in the podocyte,” said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio. “Suppressing the TRPC5-Rac1 pathway has the potential to deliver clinically meaningful benefit to patients by reducing proteinuria and, as a result, preserving native kidney function. Supported by the Phase 1 data, we are now underway with our Phase 2 TRACTION-2 study of GFB-887 in FSGS and DN, as we continue to advance our mission of protecting patients from the inevitability of dialysis and kidney transplant by delivering precision medicines for subsets of kidney disease.”
Data from the Phase 1 Clinical Trial
The primary objective of the randomized, double-blinded, placebo-controlled trial was to assess the safety, tolerability, pharmacokinetic (PK) profile and pharmacodynamics (PD) of GFB-887 in healthy volunteers. A key exploratory objective was to characterize changes in urinary Rac1. Urinary Rac1 concentration may predict therapeutic response to TRPC5 inhibition.
The study enrolled 70 subjects, who were randomized four to one to receive GFB-887 at seven dose levels (ranging from 5 mg to 900 mg) or placebo.
Primary Objective: Safety, Tolerability and PK Data
GFB-887 was observed to be well-tolerated at all doses. There were no dose-limiting toxicities, severe adverse events (AEs) or abnormalities in laboratory or clinical assessments. In total, 38 percent of subjects who received GFB-887 reported AEs, compared to 21 percent of subjects treated with placebo. GFB-887-treated subjects
SHANGHAI (Reuters) – China’s top legislative body passed a new biosecurity law aimed at preventing and managing infectious diseases, state news agency Xinhua reported late on Saturday.
The National People’s Congress Standing Committee voted to adopt the law on Saturday, according to Xinhua, and it would come into effect on April 15, 2021.
The law would establish systems for biosecurity risk prevention and control, including risk monitoring and early warning, risk investigation and assessment, and information sharing.
It would also have provisions to prevent and respond to specific biosecurity risks, including major emerging infectious diseases, epidemic and sudden outbreaks, and biotechnology research, development and application, reported Xinhua.
China had announced in May that it aimed to fast-track the passing of the biosecurity law by year-end, following the global coronavirus outbreak which was first detected in the Chinese city of Wuhan.
China has managed to nearly stamp out domestic transmissions of the coronavirus following aggressive measures to curb its spread. New infections detected last week in the eastern coastal city of Qingdao however ended China’s run of about two months without reporting a local case.
China’s health commission last reported 13 new coronavirus cases in the mainland for Oct. 17, bringing the mainland’s total number of confirmed cases to 85,672.
(Reporting by Emily Chow; Editing by Raju Gopalakrishnan)
Copyright 2020 Thomson Reuters.